CAR‐T cell therapy: personalised immunotherapy for cancer

Abstract

Tisagenlecleucel and axicabtagene ciloleucel – recently licensed for the treatment of certain patients with leukaemia or lymphoma – are the first of a new wave of personalised cancer treatments known as CAR‐T cell therapies. This article discusses their innovative mechanism of action, clinical trial efficacy, adverse effects and future place in therapy.